Plus Therapeutics Inc   (PSTV)
Other Ticker:  
Price: $2.1800 $0.05 2.347%
Day's High: $2.19 Week Perf: -3.11 %
Day's Low: $ 2.11 30 Day Perf: 33.74 %
Volume (M): 10 52 Wk High: $ 4.45
Volume (M$): $ 21 52 Wk Avg: $2.05
Open: $2.19 52 Wk Low: $0.97

 Market Capitalization (Millions $) 7
 Shares Outstanding (Millions) 3
 Employees -
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Plus Therapeutics Inc
Plus Therapeutics Inc is a biotechnology company that specializes in developing and commercializing innovative, targeted therapies for rare and difficult-to-treat cancers. Their focus is on creating novel drugs that can potentially improve outcomes for patients with limited treatment options. They aim to combine advanced drug delivery technologies with cutting-edge science to deliver more effective and personalized treatments.

   Company Address: 4200 MARATHON BLVD AUSTIN 78756 TX
   Company Phone Number: 255-7194   Stock Exchange / Ticker: NASDAQ PSTV


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Plus Therapeutics: Advancing Patient Care Through Leptomeningeal Metastases Acquisition and Foresee Clinical Trials

Published Thu, May 9 2024 3:30 PM UTC

Plus Therapeutics, an oncology-focused pharmaceutical company, recently provided updates on two major fronts??its Leptomeningeal Metastases acquisition and topline data from The Foresee (186Re) trial. Leptomeningeal metastases (LM), a severe complication of cancer, results from the spread of malignant cells to the leptomeninges, the surfaces encapsulating the brain and spina...

Financing Agreement

Plus Therapeutics Secures $3 Million Award from the U.S. Department of Defense and Shows Improvement in Debt Management

Published Mon, Apr 22 2024 11:01 AM UTC

Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense and Improves Total Debt to Equity Ratio
Plus Therapeutics Inc. has recently received a $3 million award recommendation from the United States Department of Defense, showcasing the company's continued commitment to innovation and advancement in the healthcare industry. ...

Management Changes

Plus Therapeutics Inc Bolsters Management Team with Leading Neuro-Oncologist and Distinguished Ph.D., Aims for Innovation and Growth

Published Tue, Apr 9 2024 11:00 AM UTC

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus Management Team
The healthcare industry is constantly evolving and advancing, and it is essential for companies to have access to experts in key areas. Plus Therapeutics Inc, a leading pharmaceutical company, has recently announced the addition of two highly accomplished professionals to thei...

Clinical Study

CSF-01: Unveiling the Secrets of Leptomeningeal Cancer Cells

Published Mon, Mar 25 2024 12:01 PM UTC

The diagnosis and treatment of leptomeningeal metastasis, a devastating complication of adenocarcinoma and melanoma, is often challenging due to the limited tools available for accurate identification of cancer cells in the leptomeninges. In a recent breakthrough, Plus Therapeutics has announced the successful validation and clinical implementation of a novel diagnostic test...

Clinical Study

Plus Therapeutics Announces Completion of Dosing in Cohort 5 of Groundbreaking Phase 1 Trial on Rhenium (186Re) Obisbemeda for Leptomeningeal Metastases

Published Mon, Mar 11 2024 11:00 AM UTC

Plus Therapeutics, a leading pharmaceutical company, has successfully achieved a significant milestone in its groundbreaking clinical trial investigating the efficacy of Rhenium (186Re) Obisbemeda for the treatment of Leptomeningeal Metastases (LM). Following the completion of dosing in Cohort 5, a total of 18 patients have been enrolled in the trial so far, marking an impor...


Plus Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com